Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02351336
Other study ID # PTB 012
Secondary ID
Status Recruiting
Phase N/A
First received January 22, 2015
Last updated February 15, 2015
Start date August 2014
Est. completion date February 2015

Study information

Verified date February 2015
Source Ain Shams Maternity Hospital
Contact Wessam M Abouelghar, MD
Phone 002-01227460679
Email dr.awessam@gmail.com
Is FDA regulated No
Health authority Egypt: Ain Shams Maternity Hospital
Study type Observational

Clinical Trial Summary

If the investigators could prove that three -dimensional ultrasound measurement of fetal adrenal gland volume can accurately predict the likelihood of preterm birth in patients having symptoms and signs of PTL , they would be able to use it as a valuable component for assessment and early management of high risk pregnant women for PTB which can be positively reflected on the risk of neonatal morbidity and mortality in those patients.


Description:

Preterm birth ( PTB) is one of the leading causes of neonatal morbidity and mortality Early PTB (≤ 34 weeks' gestation) carries a 7-fold increased risk of Neonatal death . Following PTB, survivors can experience significant long term cognitive, behavioral, emotional, sensory, and motor deficits. Hence, there is growing interest in the identification of women who are at Risk for spontaneous PTB. Many biophysical and biochemical markers have been discovered to identify those women who are at risk for spontaneous PTB.

Unfortunately, none of the various maternal and fetal biomarkers such as:

cytokines, CRH, C-reactive protein, fetal fibronectin ,…. etc. are sufficiently sensitive or specific to be used alone or in combination to help decrease the rate of preterm births. Obviously, there's a need for an accurate method with high sensitivity and specificity for prediction of preterm labor. So that an appropriate management or referral to a higher center can be done to women likely to have PTB. Whereas unnecessary tocolytic therapy can be avoided in women who are unlikely to have PTB. Convincing data have shown that 2-dimensional (2D) ultrasound measurement of cervical length (CL) can identify women at risk for PTB.

Accordingly, CL is now widely used in clinical practice for risk estimation. However, as understanding of the mechanisms of preterm labor (PTL) have evolved, obstetricians have learned that, in some women, cervical shortening is a phenomenon that carries no increased risk for prematurity. Therefore, the search for early and accurate markers that distinguish between physiologic processes and abnormal activation of the labor cascade has been ongoing.

Literature has suggested that activation of the fetal hypothalamic-pituitary-adrenal axis play a crucial rule in commencement of labor. A previous study demonstrated that three -dimensional ultrasound measurement of fetal adrenal gland volume (AGV) may identify women at risk for impending PTB. In a more recent study receiver operator characteristics (ROC) curve analysis revealed that three -dimensional ultrasound measurement of (AGV) was superior to two-dimensional ultrasound measurement of (AGV) for anticipation of PTB within 7 days of the scan. The aim of this study is to investigate the utility of 3D fetal adrenal gland volume measurement in the early prediction of PTB and to determine whether these measurements could be combined with 2D ultrasound cervical assessment to improve the early prediction of PTB.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

1. Age : 18 - 40 years

2. Gestational age: 26 - 35 weeks , which is going to be calculated according to the date of last menstrual period & confirmed by first trimester ultrasonography .

3. Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :

- Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )

- Cervical dilataion >1cm, &/or

- Cervical effacement = 80% 4. Women having one or more of the following:

- Multifetal pregnancy .

- Previous preterm labor or premature birth, particularly in the most recent pregnancy or in more than one previous pregnancy

Exclusion Criteria:

1. Suspected fetal growth restriction .

2. Preterm premature rupture of the membranes : confirmed by visualization of amniotic fluid vaginal pooling at the time of sterile speculum examination .

3. Patients with antepartum haemorrhage ( due to placental abruption &/or placenta previa )

4. Presence of fetal anomalies incompatible with life. 5 - Patients who are not sure of dates

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Device:
Ultrasound imaging
- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3) - corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) ) - CL measurement using 2D ultrasound ( in cm)

Locations

Country Name City State
Egypt Ain Shams Maternity Hospital Cairo

Sponsors (2)

Lead Sponsor Collaborator
Wessam Magdy Abouelghar Ain Shams Maternity Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Turan OM, Turan S, Funai EF, Buhimschi IA, Campbell CH, Bahtiyar OM, Harman CR, Copel JA, Buhimschi CS, Baschat AA. Ultrasound measurement of fetal adrenal gland enlargement: an accurate predictor of preterm birth. Am J Obstet Gynecol. 2011 Apr;204(4):311.e1-10. doi: 10.1016/j.ajog.2010.11.034. Epub 2011 Feb 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1. Accurate prediction of impending preterm birth using 3D ultrasound estimation of fetal adrenal gland volume within 7 days of ultrasound scan No
Secondary Superiority of Adrenal gland volme estimation in prediction of preterm birth compared to cervical length measurement alone 7 days of ultrasound scan No
See also
  Status Clinical Trial Phase
Completed NCT01340222 - Monocyte Chemotactic Protein-1 (MCP-1) Expressing Monocytes to Predict Preterm Delivery: PhenoMAP Study N/A
Completed NCT00568113 - N-Acetyl Cysteine for Prevention of Preterm Birth Phase 4
Not yet recruiting NCT04104984 - Detection of Preterm Labour by Cervical Length Early Phase 1
Recruiting NCT02331199 - Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity Phase 3
Completed NCT02092688 - Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth
Completed NCT02284867 - Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ? N/A
Completed NCT01429545 - Single Versus Combination Therapy in Acute Tocolysis Phase 2